Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2019 08:02 ET | Source: Vaccinex, Inc.

Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation

ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer,...
December 09, 2019 07:55 ET | Source: Vaccinex, Inc.

Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer’s Disease

ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
November 14, 2019 07:55 ET | Source: Vaccinex, Inc.

Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program

Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease ...
November 12, 2019 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 Updated interim data from the...
November 09, 2019 08:02 ET | Source: Vaccinex, Inc.

Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
September 27, 2019 06:05 ET | Source: Vaccinex, Inc.

Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France

ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
September 24, 2019 08:05 ET | Source: Vaccinex, Inc.

Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference

ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
August 14, 2019 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data...
August 13, 2019 08:05 ET | Source: Vaccinex, Inc.

Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer

63% of evaluable subjects whose tumors had progressed during prior checkpoint inhibitor therapy benefited from treatment with the combination of pepinemab and avelumab Primary completion anticipated...
July 31, 2019 07:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces $13.8 Million Private Placement

ROCHESTER, N.Y., July 31, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right